Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-bet engineered iPSC-derived NK cells
- Development stage
- Preclinical
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**T-bet engineered iPSC-derived natural killer (NK) cells** are an investigational cell therapy derived from induced pluripotent stem cells (iPSCs), genetically modified to overexpress the transcription factor T-bet (TBX21). T-bet drives epigenetic activation of an NK cell-specific transcriptome, accelerating differentiation, enhancing maturation markers like CD16 and KIR, and improving functionality including IFN-γ production, cytotoxicity, and antibody-dependent cellular cytotoxicity (ADCC). This approach overcomes limitations of primary NK cells by enabling scalable, homogeneous "off-the-shelf" production for adoptive immunotherapy, primarily targeting cancers such as hepatocellular carcinoma (HCC), with preclinical evidence of superior anti-tumor activity in TGF-β-suppressed environments when combined with CARs targeting GPC3 or AFP[1][4].
- Other names
- TBX21-overexpressing iPSC-derived NK cellsTBX-21-overexpressing iPSC-derived NK cellsTBX 21-overexpressing iPSC-derived NK cells
Beyond the preview
Go deeper on T-bet engineered iPSC-derived NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-bet engineered iPSC-derived NK cells.